Viralytics capital raising

Viralytics capital raising

Viralytics capital raising

McCullough Robertson recently acted for Viralytics Limited in a $32 million capital raising, comprised of a $28 million placement and follow-on share purchase plan to raise a maximum of $4 million.

The funds raised will go toward the advancement of the clinical program for the drug CAVATAK™; a proprietary formulation of the common cold Coxsackievirus Type A21, designed to bind to specific protein receptors found in cancers such as melanoma, as well as prostate, bladder and lung cancers. The drug is currently in Phase 2 clinical trials.

This deal was led by Partner Reece Walker, Senior Associate Ben Wood and Lawyer Naomi Benton.

In this section